Psilocybin-Assisted Therapy for Intergenerational Trauma
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorRachel Yehuda
About this trial
This is an open-label psilocybin-assisted therapy study that will examine the safety and tolerability of psilocybin-assisted therapy in the offspring of genocide survivors with mood and anxiety disorders.
The study will also investigate the efficacy of psilocybin-assisted therapy in reducing symptoms such as depression, anxiety and stress, as well as changes to the psychological effects of parental exposure to genocide, and changes to psychological resilience.
Eligibility criteria
Qualifiers
Age at least 18 years old at time of signing the informed consent
Biological child of at least one parent who directly survived/escaped a genocide
Meets diagnostic criteria for a depressive or anxiety disorder
Capable of providing informed consent and complying with study procedures
Disqualifiers
Not able to give adequate informed consent.
Was directly exposed to or survived a genocide.
Has a history of any medical condition, or any significant clinical finding on screening tests, that could make receiving psilocybin harmful.
Has acute, severe or unstable medical illness.
Trial design
Treatments tested in this trial
- Psilocybin
- Integration sessions
Treatment groups
100 Participants
are divided into 1 treatment groupSponsors and collaborators
Rachel Yehuda
Lead sponsor
Icahn School of Medicine at Mount Sinai
Sponsor institution
Source ClinicalTrials.gov